Supreme Court Hears Arguments on 'Skinny Labeling' Generic Drug Case

Apr 30, 2026

The Supreme Court heard oral arguments on April 28, 2026, in a closely watched case concerning skinny labeling, a practice where generic drug companies seek regulatory approval to market medicines for specific uses while excluding other patented uses of brand-name drugs. This carve-out tactic has been a key tool for generic manufacturers since the Hatch-Waxman Act was enacted over four decades ago to foster competition and help generic drugs enter the marketplace more readily. Justices appeared to signal the practice may survive legal challenge, which has significant implications for generic drug availability and consumer access to affordable medicines.

Skinny Labeling as a Generic Drug Strategy

▪Skinny labeling has been a key tool for generic companies ever since the Hatch-Waxman Act was signed into law more than four decades ago.
▪Skinny labeling refers to moves by generic companies that seek regulatory approval to market a medicine for a specific use, but not other patented uses for which a brand-name drug is prescribed.
▪Skinny labeling amounts to a carve-out tactic used by generic drug companies.
▪Generic companies use skinny labeling to avoid lawsuits claiming patent infringement.

Supreme Court Case and Legal Implications

▪The Supreme Court heard oral arguments on April 28, 2026 about skinny labeling.
▪The Supreme Court skinny labeling case will be closely watched for its implications for the availability of generic medicines.

Impact on Generic Drug Market Competition

▪Congress attempted to foster more competition and benefit consumers through skinny labeling as one mechanism in the Hatch-Waxman Act.
▪The Hatch-Waxman Act established the mechanisms by which generic drugs can more readily enter the marketplace.

Perspective of Generic drug companies

▪Generic drug companies argue that skinny labeling enables them to provide affordable medication alternatives to consumers without infringing on valid patents.
▪Generic drug manufacturers contend that eliminating skinny labeling would significantly delay generic drug market entry and reduce patient access to affordable medicines.

Perspective of Brand-name pharmaceutical companies

▪Pharmaceutical patent holders contend that skinny labeling undermines the incentive structure for investing in research and development of new drug applications.
▪Brand-name pharmaceutical companies argue that skinny labeling allows generic manufacturers to circumvent legitimate patent protections on specific drug uses.